PhD in Molecular and Cellular Biotechnology Applied to Health Sciences - Abel Salazar Institute of Biomedical Sciences and Faculty of Pharmacy of the University of Porto (2020), funded by FCT and the European Association for Cancer Research (EACR). Host Institution: Glycobiology in Cancer group of the Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup/i3S). Supervisor: Celso A. Reis. I have comprehensively dissected the glycosylation profile of the ErbB2 oncogenic receptor in gastric cancer, and identified, in ErbB2-driven gastric cancer cells, glycan-mediated pathways of molecular resistance to the trastuzumab monoclonal antibody, used in the clinical management of stage IV gastric cancer patients.

Integrated Master in Bioengineering , with a specialization in Molecular Biotechnology - Faculty of Engineering and Abel Salazar Institute of Biomedical Sciences of the University of Porto (2014). Host Institution: Cancer Biology and Epigenetics research group of the Portuguese Institute of Oncology of Porto (IPO-Porto): exploiting the crosstalk between c-Myc transcription factor and oncogenic/tumour suppressor microRNAs, as well as the impact of such molecular interplay in prostate carcinogenesis. 

Currently: Post-doctoral researcher at the Glycobiology in Cancer research group (Ipatimup/i3S): Structural characterization and assessment of the functional and clinical impact of specific glycosylation signatures of the ErbB2 oncogenic receptor in metastatic gastric adenocarcinoma. Fields of Expertise: Molecular Biology/Oncology; Molecular Biotechnology/Bioengineering; Cell-based genome editing and glycoengineering; Mass spectrometry-based glycomics and glycoproteomics (training received by Prof. Manfred Wuhrer (2017 and 2019), head of the Center for Proteomics and Metabolomics of the Leiden University Medical Center (CPM/LUMC), Leiden, The Netherlands).